Abeona Therapeutics shares rise 6.71% premarket after reporting Q2 net income of $108.8 million, beating Wall Street expectations.

Abeona Therapeutics, Inc. rose 6.71% in premarket trading, driven by the company's Q2 earnings report. Abeona Therapeutics reported a net income of $108.8 million, or $1.71 per share, surpassing Wall Street expectations. The company's revenue for the period was $400,000. Abeona Therapeutics shares have increased 18% since the beginning of the year and have climbed 32% in the last 12 months.